StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Stock analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a report on Thursday, May 2nd.

Minerva Neurosciences Price Performance

NASDAQ:NERV opened at $3.14 on Friday. The company’s fifty day moving average price is $2.83 and its 200-day moving average price is $4.54. Minerva Neurosciences has a 1-year low of $2.26 and a 1-year high of $13.49. The firm has a market capitalization of $21.95 million, a P/E ratio of -0.70 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.07. Equities analysts anticipate that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.